Alembic Pharmaceuticals records strong Q3 FY26 results, revenue grows 11%

Mumbai : Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter and nine months ended 31st December 2025.

Financial Highlights for Q3FY26

·         Revenue from operations increased by 11% to Rs.1,876 Cr.

·         EBITDA increased by 14% to Rs. 308 Cr

·         EBITDA Margin at 16% of revenue

·         Profit Before Exceptional Items and Tax increased by 15% to Rs 205 Cr

·         Pursuant to changes under the new labour code, the Company has recognised a one-time provision of Rs 42 Cr towards employee benefits.

·         Reported Profit After Tax after this one-time provision was at Rs.133 Cr.

Commenting on the results, Mr. Pranav Amin MD, Alembic Pharmaceuticals Limited, said, Our Q3 performance underscores the sustained momentum across our businesses supported by consistent execution, continued focus on profitability and operating rhythm. We further strengthened our presence in Australia, Canada, Europe, the USA and other key markets delivering an overall growth of 11%.  Our pre-R&D EBITDA margin at 25% remains healthy. We continued to invest around 9% of revenue in R&D to build a robust pipeline for future growth. The integration of Utility Therapeutics progressed well, and we are working towards launch of PivyaTM in quarter 4 positioning us to expand our footprint in branded drugs in the US and create new avenues for sustainable growth.

Operational Highlights

India Branded Business

·         India Branded Business delivered a 6% YoY growth, reaching Rs 652 Cr. in revenue for the quarter.

·         Gynaecology, Ophthalmology and Animal healthcare segments supported the growth for the quarter.

·         Anti-infective segment grew in line with market performance.

·         Successfully introduced 4 new products during the quarter.

International Business

·         US Generics grew by 6% to Rs. 553 Cr. for the quarter.

·         2 Launches in the US market during the quarter.

·         Ex-US International Generics grew by 36% to Rs. 406 Cr. for the quarter.

·         7 ANDA approvals received during the quarter, 232 Cumulative ANDA approvals.

API Business

·         API business grew by 2% to Rs. 264 Cr. for the quarter.

The summary of Revenue from Operations is as under: 

 (Rs in Cr.)